«

»

5月 30

Selected original publications 2017年

Selected original publications 2017年(平成29年)

 


Ahmed Hegab, Mari Ozaki, Kagawa Shizuko, Junko Hamamoto, Hiroyuki Yasuda, Katsuhiko Naoki, Kenzo Soejima, Yongjun Yin, Tomonari Kinoshita, Tomonori Yaguchi, Yutaka Kawakami, David Orntiz, and Tomoko Betsuyaku.  Tumor associated macrophages support the growth of FGF9-induced lung adenocarcinoma by multiple mechanisms. Lung Cancer. 119:25-35,2017


Kinoshita T, Kudo-Saito C, Muramatsu R, Fujita T, Saito M, Nagumo H, Sakurai T, Noji S, Takahata E, Yaguchi T, Tsukamoto N, Hayashi Y, Kaseda K, Kamiyama I, Ohtsuka T, Tomizawa K, Shimoji M, Mitsudomi T, Asamura H, Kawakami Y.  Determination of poor prognostic immune features of tumor microenvironment in nonsmoking patients with lung adenocarcinoma. European Journal of Cancer. 86:15-27,2017


Yaguchi T, Kobayashi A, Inozume T, Morii K, Nagumo H, Nishio H, Iwata T, Ka Y, Katano I, Ito R, Ito M, Kawakami Y.  Human PBMC transferred murine MHC class I/II deficient NOG mice enable long-term evaluation of human immune responses. Cellular & Molecular Immunology. 14:1-10,2017


Fukui M, Ogawa Y, Mukai S, Kamoi M,  Asato T, Kawakami Y, Tsubota K. Reduced Expression of VAMP8 in Lacrimal Gland Affected by Chronic Graft-versus-Host Disease.   Journal of Ophthalmology. 2017Article ID 1639012: 10 pages,2017


Matsushita M, Ozawa K, Suzuki T, Nakamura M, Nakano N, Kanchi S, Ichikawa D, Matsuki E, Sakurai M, Karigane D, Kasahara H, Tsukamoto N, Shimizu T, Mori T, Nakajima H, Okamoto S, Kawakami Y, Hattori Y.  CXorf48 is a potential therapeutic target for achieving treatment-free remission in CML patients. Blood Cancer Journal. 7:e601,2017


Shindo Y, Hazama S, Nakamura Y, Inoue Y, Kanekiyo S, Suzuki N, Takenouchi H, Tsunedomi R, Nakajima M, Ueno T, Takeda S, Yoshino S, Okuno K, Fujita Y, Hamamoto Y, Kawakami Y, Oka M, Nagano H.  miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer. Oncol Lett. 14(2):1355-1362,2017


Ohta S, Kawakami Y and Okano H. MIF: functions in brain and glioblastoma. Oncotarget. 8(29):46706-46707,2017


Jinushi M, Morita T, Xu Z, Kinoshita I, Dosaka-Akita H,  Yagita H, Kawakami Y.  Autophagy-dependent regulation of tumor metastasis by myeloid cells. PLOS ONE. 12(7):e0179357,2017


Hayashi H, Chiba Y, Sakai K, Fujita T, Yoshioka H, Sakai D, Kitagawa C, Naito T, Takeda K, Okamoto I, Mitsudomi T, Kawakami Y, Nishio K, Nakamura S, Yamamoto N, Nakagawa K. A randomized phase II study comparing nivolumab with carboplatin-pemetrexed for patients with EGFR mutation-positive nonsquamous non-small cell lung cancer who acquire resistance to tyrosine kinase inhibitors not due to a secondary T790M mutation: rationale and protocol design for the WJOG8515L study. Clin. Lung Cancer. S1525-7304(17)30147-X.:,2017


Katano I, Nishime C, Ito R, Kamisako T, Mizusawa T, Ka Y, Ogura T, Suemizu H, Kawakami Y, Ito M, Takahashi T.  Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse. Sci Rep.7(1):17230,2017


Xu Z, Shioda S, Jinushi M, Kawakami Y, Ohtaki H, Wang S, Zhao X, Liu Y, Zhou D, Guo Y.  Role of the autonomic nervous system in the tumor micro-environment and its therapeutic potential. Curr Pharm Des. 23(11):1687-1692,2017


Kato D, Yaguchi T, Iwata T, Morii K, Nakagawa T, Nishimura R, Kawakami Y.  Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies. Jpn J Clin Immunol.  in press,:,2016


Miyauchi T, Yaguchi T, Kawakami Y.  Inter-patient and Intra-tumor Heterogeneity in the Sensitivity to Tumor-targeted Immunity in Colorectal Cancer. Jpn J Clin Immunol. in press,:,2016


Shindo Y, Hazama S, Suzuki N, Iguchi H, Uesugi K, Tanaka H, Aruga A, Hatori T, Ishizaki H, Umeda Y, Fujiwara T, Ikemoto T, Shimada M, Yoshimatsu K, Takenouchi H, Matsui H, Kanekiyo S, Iida M, Koki Y, Arima H, Furukawa H, Ueno T, Yoshino S, Fujita T, Kawakami Y, Nakamura Y, Oka M, Nagano H. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. J Exp Clin Cancer Res.36(1):36,2017


Mukai S, Ogawa Y, Urano F, Kudo-Saito C, Kawakami Y, Tsubota K. Novel Treatment of Chronic Graft-Versus-Host Disease in Mice Using the ER Stress Reducer 4-Phenylbutyric AcidSci. Rep. 7:41939:,2017


Mori M, Funakoshi T, Kameyama K, Kawakami Y, Sato E, Nakayama E, Amagai M, Tanese K.  Lack of XAGE-1b and NY-ESO-1 in metastatic lymph nodes may predict the potential survival of stage III melanoma patients. J Dermatol.  [Epub ahead of print]:,2017


Miyazaki J, Ito K, Fujita T, Matsuzaki Y, Asano T, Hayakawa M, Asano T, Kawakami Y. Progression of Human Renal Cell Carcinoma via Inhibition of RhoA-ROCK Axis by PARG1. Transl Oncol.10(2):142-152,2017


Fukuda K, Funakoshi T, Sakurai T, Nakamura Y, Mori M, Tanese K, Tanikawa A, Taguchi J, Fujita T, Okamoto M, Amagai M, Kawakami Y. Peptide-pulsed dendritic cell vaccine in  combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma. Melanoma Research. [Epub ahead of print]:,2017


Saito K, Ohta S, Kawakami Y, Yoshida K, Toda M.  Functional analysis of KIF20A, a potential immunotherapeutic target for glioma.  Journal of Neuro-Oncology. 132(1):63-74,2017